Pekin Hardy Strauss Inc. Has $10.09 Million Stock Holdings in Humana Inc. (NYSE:HUM)

Pekin Hardy Strauss Inc. increased its holdings in shares of Humana Inc. (NYSE:HUM) by 3.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,849 shares of the insurance provider’s stock after purchasing an additional 1,029 shares during the period. Humana makes up 1.3% of Pekin Hardy Strauss Inc.’s portfolio, making the stock its 9th biggest position. Pekin Hardy Strauss Inc.’s holdings in Humana were worth $10,088,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Mendota Financial Group LLC raised its stake in shares of Humana by 9.2% in the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after purchasing an additional 27 shares during the period. Capital Advisors Ltd. LLC raised its position in Humana by 17.0% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock valued at $80,000 after buying an additional 31 shares during the last quarter. CarsonAllaria Wealth Management Ltd. raised its position in Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after buying an additional 39 shares during the last quarter. Moors & Cabot Inc. increased its position in shares of Humana by 2.5% during the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after purchasing an additional 40 shares during the last quarter. Finally, Harbour Investments Inc. raised its stake in shares of Humana by 10.5% during the 2nd quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider’s stock worth $161,000 after purchasing an additional 41 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Price Performance

Shares of HUM stock opened at $298.11 on Friday. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $527.18. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The business has a fifty day simple moving average of $276.83 and a 200 day simple moving average of $330.68. The company has a market cap of $35.90 billion, a P/E ratio of 26.40, a P/E/G ratio of 2.33 and a beta of 0.52.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, sell-side analysts forecast that Humana Inc. will post 15.86 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.19%. Humana’s dividend payout ratio (DPR) is presently 31.36%.

Analyst Ratings Changes

Several equities analysts recently weighed in on HUM shares. Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 target price on shares of Humana in a research note on Tuesday, October 1st. Stephens reiterated an “equal weight” rating and issued a $250.00 price target on shares of Humana in a research note on Wednesday, October 9th. Piper Sandler lowered Humana from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $392.00 to $274.00 in a research note on Thursday, October 3rd. TD Cowen lifted their price target on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Finally, Jefferies Financial Group downgraded shares of Humana from a “buy” rating to a “hold” rating and decreased their price target for the company from $519.00 to $253.00 in a research note on Monday, October 7th. Twenty equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.